FUROSEMIDE (furosemide) by R-Pharm US is clinical pharmacology investigations into the mode of action of furosemide have utilized micropuncture studies in rats, stop flow experiments in dogs and various clearance studies in both humans and experimental animals. Approved for heart failure, essential hypertension.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
Furosemide is a loop diuretic that inhibits sodium and chloride reabsorption in the proximal tubule, distal tubule, and loop of Henle, making it highly effective for fluid overload management. It is indicated for heart failure and essential hypertension, with oral tablet formulation offering 64% bioavailability and a 2-hour duration of effect. The drug works as a potent diuretic with rapid onset (within 5 minutes IV, peak effect within 30 minutes) and is extensively protein-bound at therapeutic concentrations.
Pre-launch stage indicates a newly developed or repositioned formulation with potential for significant commercial build-out; commercial team will focus on market access, payer negotiations, and field force deployment.
CLINICAL PHARMACOLOGY Investigations into the mode of action of furosemide have utilized micropuncture studies in rats, stop flow experiments in dogs and various clearance studies in both humans and experimental animals. It has been demonstrated that furosemide inhibits primarily the reabsorption…
Worked on FUROSEMIDE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Bumetanide vs. Furosemide in Cirrhosis
A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)
Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteers
A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on a pre-launch branded generic offers rare opportunity to build a product from market entry, with emphasis on payer negotiations, formulary placement, and field execution in a crowded but stable market. Career growth depends on successful differentiation strategy and ability to capture market share from established generics and newer competitors.